secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001193125-23-206235
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q2 revenue up 24% to $49.7M; net loss widens to $4.4M
-----------------------------------------------------------

- Revenue $49.7M (+24% YoY); organic revenue $41.5M (+3%) excl. $8.2M from Luminex acquisition.
- Gross margin 57% vs 61% YoY; adjusted gross margin 60% vs 64%.
- Operating loss $9.1M (vs $0.9M loss Q2 2022); net loss $4.4M (vs $0.7M).
- Adjusted EBITDA $1.5M vs $4.8M prior year; cash $298.8M.
- Shipped 100th Cytek Aurora Cell Sorter; FY2023 revenue guidance reaffirmed at $205M-$220M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523206235/0001193125-23-206235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523206235/d440092d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-206235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer